A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 353 participants.
Also called NCT04998981
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 353 participants
- Sponsor
- Registry
-
NCT04998981
-
- Other papers using this trial's data
- Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04998981. Randomized; quadruple masking; primary purpose treatment. Start 2021-09-17 (actual); primary completion 2023-02-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C
- Condition
- Hyperlipidemia
- Intervention (Drug)
- K-877 0.1 mg tablet
- Intervention (Drug)
- Fenofibrate 200 mg capsule
- Intervention (Drug)
- Placebo tablet
- Intervention (Drug)
- Placebo capsule
- Intervention (Drug)
- K-877 0.1 mg tablet
- Intervention (Drug)
- Placebo tablet
- Lead sponsor
- Kowa Company, Ltd.
Record details
- Record id
cardio:ct-nct04998981- Content hash
977c9a5b6de6a485a94d4a9213f9d2572a2f9eac55873b9472ebb11c63dfb6f9